Prosecution Insights
Last updated: April 19, 2026
Application No. 17/725,228

SYNERGISTIC COMBINATIONS OF OX40L ANTIBODIES FOR THE TREATMENT OF GVHD

Non-Final OA §DP
Filed
Apr 20, 2022
Examiner
OUSPENSKI, ILIA I
Art Unit
1644
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Kymab Limited
OA Round
3 (Non-Final)
78%
Grant Probability
Favorable
3-4
OA Rounds
2y 10m
To Grant
98%
With Interview

Examiner Intelligence

Grants 78% — above average
78%
Career Allow Rate
850 granted / 1097 resolved
+17.5% vs TC avg
Strong +20% interview lift
Without
With
+20.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 10m
Avg Prosecution
42 currently pending
Career history
1139
Total Applications
across all art units

Statute-Specific Performance

§101
1.7%
-38.3% vs TC avg
§103
10.6%
-29.4% vs TC avg
§102
19.1%
-20.9% vs TC avg
§112
17.3%
-22.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1097 resolved cases

Office Action

§DP
DETAILED ACTION 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . 2. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 01/30/2026 has been entered. 3. Applicant's amendment and remarks filed on 01/30/2026 are acknowledged. Claims 1-9, 15-20, 22, 24 and 28-32 are pending. 4. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP §§ 706.02(l)(1) - 706.02(l)(3) for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp. 5. Claims 1-9, 15-20, 22, 24 and 28-32 stand rejected on the ground of nonstatutory double patenting as being unpatentable over the claims of the following U.S. Patents (all of record): 9434785, 9512229, 9868789, 9868790, 9139653, 9587030, 10654935, 11396550, 11753479, 11773175, and 11779604. Claims 1-9, 15-20, 22, 24 and 28-32 stand provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over the claims of the following copending applications (all of record): USSN 17/818397 (US PG Pub. No. 20230235069), USSN 18/364906 (US PG Pub. No. 20240132605), USSN 18/459995 (US PG Pub. No. 20240122985), and USSN 19/030346 (US PG Pub. No. 20250263492). The grounds of rejection presented in Sections 4-7 of the previous Office action (dated 10/30/2025) are maintained for the reasons of record, and are incorporated by reference herein as if reiterated in full. Regarding US Patents No. 9434785, 9512229, 9868789 and 9868790, “Applicant will consider the merits of filing a Terminal Disclaimer over the '785 patent, the '229, the '789 patent, and the '790 patent once the subject claims are otherwise indicated to be in condition for allowance.” (p. 8 of the Remarks) Regarding all other US Patents and all copending applications referenced above, Applicant’s arguments have been fully considered but have not been found convincing. Applicant alleges that the referenced patents and applications do not qualify as proper nonstatutory double patenting references over the subject application, because the Office has not sufficiently established that the instant claims, if granted, would effectively extend the life of the reference patents, or patents issuing from the referenced copending applications. Applicant cites PTAB decisions in Ex Parte NICOLAS BAURIN, 11-04-2024 and 12-08-2025, in support of the stated position. In response, Applicant's reliance on Ex parte Baurin is ineffective in overcoming the rejections of record, at least because the decision is not precedential AND is not consistent with MPEP 804.02. MPEP 804 does not instruct examiners to predict the expiration date of a patent that may issue from an application as a basis for making a double patenting rejection. Such prediction would not be possible, because determinations of patent term adjustments and extensions are not made during examination. The Examiner has no authority to disqualify a double patenting reference having conflicting claims and a common assignee and/or inventor based on applicant’s asserted expiration date analysis. Importantly, the “risk of separate ownership” is one of the two public policy concerns underlying nonstatutory double patenting doctrine, as evidenced by MPEP 804.02(IV): ‘Each one of the commonly owned conflicting nonstatutory double patenting references must be included in the terminal disclaimer to avoid the problem of dual ownership of patents to patentably indistinct inventions in the event that the patent issuing from the application being examined ceases to be commonly owned with any one of the double patenting references that have issued or may issue as a patent. Note that 37 CFR 1.321(c)(3) requires that a terminal disclaimer for commonly owned conflicting claims “[i]nclude a provision that any patent granted on that application or any patent subject to the reexamination proceeding shall be enforceable only for and during such period that said patent is commonly owned with the application or patent which formed the basis for the judicially created double patenting.”’ Accordingly, the rejections are maintained. 6. Conclusion: no claim is allowed. 7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ILIA I OUSPENSKI whose telephone number is (571)272-2920. The examiner can normally be reached 9 AM - 5:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Julie Wu can be reached at 571-272-5205. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ILIA I OUSPENSKI/ Primary Examiner, Art Unit 1644
Read full office action

Prosecution Timeline

Apr 20, 2022
Application Filed
Jun 11, 2025
Non-Final Rejection — §DP
Sep 15, 2025
Response Filed
Oct 28, 2025
Final Rejection — §DP
Jan 30, 2026
Request for Continued Examination
Feb 02, 2026
Response after Non-Final Action
Mar 05, 2026
Non-Final Rejection — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600776
ANTI-L1CAM ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND CHIMERIC ANTIGEN RECEPTOR COMPRISING SAME
2y 5m to grant Granted Apr 14, 2026
Patent 12590153
TREATMENT OF PD-L1-NEGATIVE MELANOMA USING AN ANTI-PD-1 ANTIBODY AND AN ANTI-CTLA-4 ANTIBODY
2y 5m to grant Granted Mar 31, 2026
Patent 12590154
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
2y 5m to grant Granted Mar 31, 2026
Patent 12583903
CONSTRUCTION OF CHIMERIC ANTIGEN RECEPTOR TARGETING CD20 ANTIGEN AND ACTIVITY IDENTIFICATION OF ENGINEERED T CELLS THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12583934
ANTI-CD26 ANTIBODIES AND USES THEREOF
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
78%
Grant Probability
98%
With Interview (+20.5%)
2y 10m
Median Time to Grant
High
PTA Risk
Based on 1097 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month